Hide
CMS156v2 and CMS156v3 numerator includes all patients who have meet IPP and DEM with an order for at least one high-risk medication during the measurement period. The improvement notation also indicates 'Lower score indicates better quality'. As result, is this a provider specific measure and should the numerator only increment for the provider who has prescribed the high-risk medication ? If so we should exclude all medications prescribed elsewhere from numerator, correct? This way the high-risk medication prescriptions prescribed by a provider will not count against other providers performance if the numerator will exclude medications prescribed elsewhere. See example below:
Example:
If a patient is new to the practice and see provider A. A chart abstraction is performed and add a high-risk med that was prescribed by one of the patient's previous physicians to the chart, should that count against provider A, even if the medication was not prescribed by this provider?
Show
CMS156v2 and CMS156v3 numerator includes all patients who have meet IPP and DEM with an order for at least one high-risk medication during the measurement period. The improvement notation also indicates 'Lower score indicates better quality'. As result, is this a provider specific measure and should the numerator only increment for the provider who has prescribed the high-risk medication ? If so we should exclude all medications prescribed elsewhere from numerator, correct? This way the high-risk medication prescriptions prescribed by a provider will not count against other providers performance if the numerator will exclude medications prescribed elsewhere. See example below:
Example:
If a patient is new to the practice and see provider A. A chart abstraction is performed and add a high-risk med that was prescribed by one of the patient's previous physicians to the chart, should that count against provider A, even if the medication was not prescribed by this provider?